Amyloidosis as a cause or factor in the progression of cardiorenal damage

7th International Congress of Cardionephrology KARNEF (2025) [pp. 35-43]

AUTHOR(S) / АУТОР(И): Suzzane R. Hayman 

Download Full Pdf   

DOI: 10.46793/KARNEF25.036H

ABSTRACT / САЖЕТАК:

The amyloidoses are a group of protein folding disorders in which a protein misfolds from the normal α helical configuration into a β pleated sheet. This results in insolubility and extracellular deposition of fibrillar protein into organs. There are currently 42 proteins that have been identified as amyloidogenic. Approximately 16 have been recognized to affect the kidney, while approximately 11 proteins can deposit in the heart. The amyloidosis that frequently affects both the heart and kidney is amyloid light-chain (AL) amyloidosis. The most common symptoms related to amyloidosis, especially AL, are fatigue, dyspnea, and unintentional weight loss, which occur in more than half of patients. Given the non-specific nature of these symptoms, the diagnosis understandably is not typically high in the differential diagnosis. There are several methods employed to identify subtypes of amyloidosis: the most used is immunohistochemistry (with a panel of known antibodies against, most commonly AA, λ and ҝ light chains, and TTR), while the gold standard is laser microdissection with LC-MS/shotgun proteomics (has high sensitivity/specificity and can identify rare amyloid proteins and different amyloids that may exist concurrently). The therapeutic strategies depend on the diagnosed type of amyloidosis and are briefly discussed in the text.

KEYWORDS / КЉУЧНЕ РЕЧИ:

amyloidosis, AL (light chain amyloidosis), ATTR (transthyretin amyloidosis)

REFERENCES / ЛИТЕРАТУРА:

  • Dasari S, Theis JD, Vrana JA, Rech KL, Dao LN, Howard MT, et al. Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clin Proc. 2020;95(9):1852-64.
  • Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM, et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022;29(4):213-9.
  • Leung N, Nasr SH. 2024 Update on Classification, Etiology, and Typing of Renal Amyloidosis: A Review. Am J Kidney Dis. 2024;84(3):361-73.
  • Gonzalez-Lopez E, McPhail ED, Salas-Anton C, Dominguez F, Gertz MA, Dispenzieri A, et al. Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2024;83(11):1085-99.
  • Hester LL, Gifkins DM, K MB, Vermeulen J, Schecter JM, Strony J, et al. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. Eur J Haematol. 2021;107(4):428-35.
  • Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am J Hematol. 2024;99(2):309-24.
  • Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-68.
  • García de Oteyza G, Laiseca A, Sauvageot P, Álvarez de Toledo J. Methicillin-Resistant Staphylo-coccus aureus Acute Keratitis After Intracorneal Ring Segment Implantation. Ophthalmol Ther. 2017;6(2):367-71.
  • Gertz MA. Cardiac Amyloidosis. Heart Fail Clin. 2022;18(3):479-88.
  • Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and Survival Trends in Amyloidosis, 1987-2019. N Engl J Med. 2020;382(16):1567-8.
  • González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94.
  • Maurizi N, Rella V, Fumagalli C, Salerno S, Castelletti S, Dagradi F, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol. 2020;300:191-5.
  • Bruno M, Castaño A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev. 2021;26(1):35-45.
  • Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022;24(12):2342-51.
  • Kaku M, Berk JL. Neuropathy Associated with Systemic Amyloidosis. Semin Neurol. 2019; 39(5):578-88.
  • Tana M, Tana C, Rossi D, Mantini C, Gallina S, Ricci F, et al. Thromboembolic and bleeding risk in cardiac amyloidosis. J Thromb Haemost. 2024;22(9):2381-92.
  • Abdallah N, Muchtar E, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, et al. Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clin Proc. 2021;96(2):377-87.
  • Napolitano A, De Michieli L, Sinigiani G, Berno T, Cipriani A, Spiezia L. Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review. J Clin Med. 2023;12(20).
  • Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12.
  • Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-95.
  • Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113 (10):1723-7.
  • Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, et al. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med. 2017;49(7):545-51.
  • Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, et al. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021;96(6):1546-77.
  • Eirin A, Irazabal MV, Gertz MA, Dispenzieri A, Lacy MQ, Kumar S, et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2012;27(3):1097-101.
  • Gibier JB, Gnemmi V, Glowacki F, Boyle EM, Lopez B, MacNamara E, et al. Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis. Mod Pathol. 2018;31(3):452-62.
  • Said SM, Best Rocha A, Valeri AM, Paueksakon P, Dasari S, Theis JD, et al. The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis. Kidney Int. 2022;101(1):152-63.
  • Chowdhury R, Shah S, Latcha S, Lobato L. Kidney Disease in Systemic Amyloidosis: A Review of Amyloid, Amyloid Serum A Protein, Leukocyte Chemotactic Factor 2, and Transthyretin Amy-loid. Kidney360. 2024;5(12):1925-37.
  • Solignac J, Delmont E, Fortanier E, Attarian S, Mancini J, Daniel L, et al. Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients. Clin Kidney J. 2022;15 (9):1747-54.
  • Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B. Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int. 2008;74(2):218-22.
  • Larsen CP, Kossmann RJ, Beggs ML, Solomon A, Walker PD. Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis. Kidney Int. 2014;86(2):378-82.
  • Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515-23.
  • Larsen CP, Beggs ML, Wilson JD, Lathrop SL. Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico. Amyloid. 2016;23 (2):119-23.
  • Mann BK, Bhandohal JS, Cobos E, Chitturi C, Eppanapally S. LECT-2 amyloidosis: what do we know? J Investig Med. 2022;70(2):348-53.
  • Larsen CP, Ismail W, Kurtin PJ, Vrana JA, Dasari S, Nasr SH. Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians. Mod Pathol. 2016;29(4):416-20.
  • Said SM, Sethi S, Valeri AM, Chang A, Nast CC, Krahl L, et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014;86(2):370-7.
  • Suhr OB, Grogan M, Silva AMD, Karam C, Garcia-Pavia P, Drachman B, et al. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid. 2025;32(1):14-21.
  • Stein AP, Matthia EL, Petty SA, Stewart B, Vilaro JR, Al-Ani MAZ, et al. Transthyretin Cardiac Amyloidosis Disguised as Light Chain Amyloidosis or Multiple Myeloma? Am J Cardiol. 2024;210:85-92.
  • Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517-35.